Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum subspecies infantis BLI-02
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
bifidobacterium longum subspecies infantis BLI-02 is a proprietary probiotic strain developed by Synbio Tech, specifically isolated for its robust ability to colonize the human gastrointestinal tract. As a subspecies of *B. longum*, it is uniquely equipped with a comprehensive suite of genes dedicated to the transport and catabolism of human milk oligosaccharides (HMOs), which are complex carbohydrates found in breast milk that remain undigested by the host. By efficiently utilizing HMOs, BLI-02 gains a competitive advantage in the infant gut, promoting a bifidogenic environment that suppresses the growth of potential pathogens through competitive exclusion and the production of organic acids like acetate and lactate. Clinically, BLI-02 has been incorporated into dietary supplements and functional foods aimed at improving digestive health, reducing symptoms of infant colic, and supporting immune system maturation.
- Brand names
- BLI-02BLI02BLI 02
- Other names
- Bifidobacterium longum subsp. infantis BLI-02Bifidobacterium infantis BLI-02B. infantis BLI-02Bifidobacterium longum BLI-02
Beyond the preview
Go deeper on bifidobacterium longum subspecies infantis BLI-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum subspecies infantis BLI-02.